Loading page…

Mangalam Drugs And Organics Limited (MANGALAM) · mywealthgrid

About

Mangalam Drugs And Organics Limited operates in Pharmaceuticals within the Healthcare sector.

Face value: ₹10

Market cap

₹46 Cr

P/E

—

P/B

0.4×

Dividend yield

ROE

-35.2%

ROCE

-22.1%

Debt / equity

1.02

OPM

-6.4%

EPS (TTM)

₹-24.2

Book value

₹65.1

52-week high

₹72.8

52-week low

₹23.8

₹29.2-59.6%1Y

Beta

0.88

Moves with the index

Volatility (1y)

54.4%

Annualised, daily returns

RSI (14)

30.9

Neither overbought nor oversold

Rel. strength (1y)

-69.4%

Behind the market

Beta is measured against NIFTY 50 over three years of weekly returns — 1 moves with the index, above 1 amplifies it, below 1 damps it.

Quick read

rule-based

Pros

No positive flags triggered.

Cons

−Low return on equity of -12.3% (3-yr avg)
−Revenue shrank over the last 5 years (-9.6% a year)
−Weak interest coverage of -2×
−Promoter holding fell 14.7 pts over the last year
−Trading 60% below its 52-week high

Research score

Structured signal from quality, growth, valuation and momentum.

34/100

Business quality: 10
Growth: 8
Valuation

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	385	451	372	369	318	232
COGS	—	—	—	245	167	157
Gross profit	—	—	—	124	151	75
	—	—	—	107	115	90
	58	49	26	17	36	-15
OPM %	15.1%	10.9%	6.9%	4.7%	11.3%	-6.4%
Depreciation	9	10	11	15	17	18
Interest	9	11	13	14	15	16
	0	0	0	0	1	1
Profit before tax	40	28	2	-11	5	-49
Tax	—	—	—	-2	-2	-4
Tax %	—	—	—	-18.1%	-40.3%	-8.6%
	28	20	1	-9	7	-44
PAT margin %	7.3%	4.4%	0.3%	-2.5%	2.1%	-19.1%
EPS (₹)	—	—	—	-5.7	4.3	-28.1
EPS adjusted (₹)	17.7	12.4	0.8	-5.7	4.3	-28.1
Annual report	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	16	16	16	16	16	16
Reserves	115	135	136	120	133	87
	58	72	68	88	81	105
	75	106	139	110	136	106
Total equity & liabilities	264	328	360	333	366	315
	103	115	108	125	163	155
CWIP	—	—	—	0	0	0
Investments	—	—	—	0	0	0
	—	—	—	208	204	160
Total assets	264	328	360	333	366	315

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	28	26	40	-11	43	4
	-31	-27	-22	0	-19	-12
	3	3	-17	0	-22	6
Net cash flow	-1	1	1	-11	1	-2
Free cash flow	—	—	—	-11	22	-8
CFO / Operating profit %	47.5%	52.4%	154.9%	-63.7%	118.9%	—

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	—	33.7%	47.4%	32.4%
EBITDA margin %	15.1%	10.9%	6.9%	4.7%	11.3%	-6.4%
EBIT margin %	12.7%	8.6%	3.9%	0.7%	6%	-14.3%
PAT margin %	7.3%	4.4%	0.3%	-2.5%	2.1%	-19.1%
Working capital
Receivable days	—	—	—	28	45	63
Inventory days	—	—	—	185	303	239
Payable days	—	—	—	98	199	177
NWC days	—	—	—	114	149	126
Leverage
Current ratio	1.23	1.4	1.25	1.07	1.04	0.79
Debt to EBITDA	1	1.47	2.68	5.06	2.27	—
Debt to equity	0.44	0.48	0.45	0.65	0.54	1.02
Interest coverage	5.2	3.5	1.2	0.2	1.3	-2
Asset turnover	1.46	1.37	1.04	1.11	0.87	0.74
Return ratios
Return on assets %	10.6%	6%	0.4%	-2.7%	1.8%	-14.1%
Return on capital employed %	31.5%	22%	7.6%	1.6%	11.4%	-22.1%
Return on equity %	21.4%	13.1%	0.8%	-6.7%	4.5%	-43.1%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	50.32%	50.32%	50.32%	50.32%	50.3%	50.3%	50.3%	50.3%	50.3%	35.64%	35.65%	35.65%
	0.1%	0.1%	0.26%	0.21%	0.11%	0.11%	0.47%	0.53%	0.11%	0.13%	0.32%	0.11%
DII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	49.58%	49.58%	49.42%	49.47%	49.59%	49.59%	49.23%	49.17%	49.59%	64.23%	64.03%	64.24%
No. of shareholders	—	—	—	—	—	—	—	—	19,881	21,227	25,140	24,465

Promoter holding down 14.67 percentage points since Sep 2023.

1 disclosure

Person	Deal	Shares	Value	Holding	Filed
SHRI JB PHARMA PRIVATE LIMITEDPromoter Group	PledgePledge Creation	17,00,000	₹14.63 cr	16.74% → 16.74%	14 Aug 20257(2)

Disclosed under SEBI’s insider-trading regulations, which require a filing only above ₹10 lakh in a quarter — smaller dealings are in no disclosure. Holdings are the filer’s own percentages, not recomputed.

76 deals · 12 Jan 2022 – 3 Feb 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
3 Feb 2026	NEO APEX VENTURE LLP	Bulk	NSE	Sell	3,50,000	₹37.90	₹1.33 Cr
3 Feb 2026	NEO APEX VENTURE LLP	Bulk	BSE	Sell	1,05,753	₹38.01	₹0.40 Cr
2 Feb 2026	NEO APEX VENTURE LLP	Bulk	NSE	Buy	4,55,753	₹32.68	₹1.49 Cr
13 Jan 2026	JYOTIPRASAD TAPARIA	Bulk	NSE	Sell	1,50,000	₹42.64	₹0.64 Cr
13 Jan 2026	SANJAY KUMAR SAINI	Bulk	NSE	Sell	95,000	₹40.65	₹0.39 Cr
12 Jan 2026	ASHUTOSH TAPARIA	Bulk	NSE	Sell	2,00,000	₹40.61	₹0.81 Cr
12 Jan 2026	SHIVKUMAR DAMANI	Bulk	NSE	Sell	81,999	₹40.61	₹0.33 Cr
9 Jan 2026	EPITOME TRADING AND INVESTMENTS	Bulk	BSE	Sell	1,34,064	₹38.77	₹0.52 Cr
9 Jan 2026	SANJAY KUMAR SAINI	Bulk	BSE	Buy	95,000	₹38.77	₹0.37 Cr
8 Jan 2026	EPITOME TRADING AND INVESTMENTS	Bulk	NSE	Buy	1,00,000	₹36.84	₹0.37 Cr

1–10 of 76

1 / 8

Mr. GOVARDHAN MURLIDHAR DHOOTExecutive Director-Chairperson-MD
Mr. BRIJMOHAN MURLIDHAR DHOOTExecutive Director
Mrs. NIDHI SHANTANU MUNDADANon-Executive - Independent Director
Mr. PRAVEEN SAXENANon-Executive - Independent Director
Mr. RAKESH KISHINCHAND MILWANINon-Executive - Non Independent Director
Mr. Jeevan Mukund DalviChief Financial Officer
Ms. Shweta PatelCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Mangalam Drugs And Organics Limited. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Credit ratings

Disclosure of change in credit rating as received from CRISIL3 Feb 2026 from CRISIL

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Interim dividend21 Dec 2017 · ex-date₹0.5

1

Board meeting to consider results12 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

12 announcementsExport CSV

1 Oct 2026, 2:34 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

Postal Ballot PDF

28 Sept 2026, 11:55 amOthers

Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A PDF

15 Sept 2026, 6:39 pmOthers

Defaults under Para A sub-paragraph 6 of Schedule III-Subsequent Disclosure

Exchange filing PDF

15 Sept 2026, 4:32 pmCompany Update

Announcement under Regulation 30 (LODR)-Change in Management

Change in Management PDF

15 Sept 2026, 4:14 pmBoard Meeting

Board Meeting Outcome for Outcome Of Board Meeting Pursuant To Regulation 30 Of LODR For Appointment Of Mr. Prabhakar Zavar As Additional Indepedent Director ( Non-Executive) For Term Of 5 Years Wef. 15/09/2026, Subject To Consent Of Shareholders At Ensuing EGM.

Outcome of Board Meeting PDF

1 Sept 2026, 5:35 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

31 Aug 2026, 5:59 pmOthers

Reg. 34 (1) Annual Report.

Reg. 34 (1) Annual Report PDF

31 Aug 2026, 5:52 pmAGM/EGM

Intimation Of 53Rd Annual General Meeting To Be Held On Wednesday, September 23Rd, 2026.

AGM PDF

Date	Category	Subject	Filing
1 Oct 2026, 2:34 pm	AGM/EGM Postal Ballot	Shareholder Meeting / Postal Ballot-Notice of Postal Ballot	PDF
28 Sept 2026, 11:55 am	Others Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A	Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

Loading announcements…

Mangalam Drugs And Organics Limited

Mangalam Drugs And Organics Limited

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Credit ratings

Events

1

1

Announcements

Not in the F&O segment

No fund holdings on record

1

1

Announcements

Annual reports

Credit ratings

Compounded sales growth

Stock price CAGR

Return on equity

Mangalam Drugs And Organics Limited

Mangalam Drugs And Organics Limited

About

Risk & technicals

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Ratios

Ratio timeline

Shareholding

Quarterly record

Insider dealing

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Credit ratings

Events

Dividends1

Board meetings1

Announcements

Not in the F&O segment

No fund holdings on record

Dividends1

Board meetings1

Ratio timeline

Announcements

Annual reports

Credit ratings

Quarterly record

Insider dealing

Bulk & block deals

Board and management

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Stock price CAGR

Return on equity

1

1

1

1